Jacob Stephen Thomas, MD, discusses safety data with ipatasertib plus pembrolizumab in metastatic HNSCC.
Jacob Stephen Thomas, MD
Advertisement
Jacob Thomas, MD, is an assistant professor of clinical medicine and service chief of LAC+USC Oncology at Keck School of Medicine of the University of Southern California.
Articles by Jacob Stephen Thomas, MD
Jacob Stephen Thomas, MD, discussed the efficacy of first-line ipatasertib plus pembrolizumab in patients with recurrent or metastatic HNSCC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
pTVG-HP DNA Vaccine Extends Overall Survival vs Placebo in PSA-Recurrent Prostate Cancer
5